Search Immortality Topics:

Page 20«..10..19202122..3040..»

Puma Biotechnology, Inc. (PBYI): From Top to Bottom – StockNewsJournal

Posted: August 31, 2017 at 4:41 pm

Puma Biotechnology, Inc. (PBYI) is an interesting player in the Healthcare space, with a focus on Biotechnology. The stock has been active on the tape, currently trading at $92.05, down from yesterdays close by -2.23%. Given the stocks recent action, it seemed like a good time to take a closer look at the companys recent data.

Fundamental Analysis

Money managers are always interested in a company that can find the right recipe of fundamental data because it reflects something important going on underneath the surface. Puma Biotechnology, Inc. (PBYI) currently trades with a market capitalization of $3.36 Billion.

The balance sheet health of any company plays a key role in its ability to meet its obligations and maintain the faith of its investment base. For PBYI, the company currently has $80.82 Million of cash on the books. You can get a sense of how sustainable that is by a levered free cash flow of $-158.57 Million over the past twelve months. Generally speaking, earnings are expected to grow in coming quarters. Analysts are forecasting earnings of $-2.36 on a per share basis this quarter. Perhaps, that suggests something about why 94.40% of the outstanding share supply is held by institutional investors.

Technical Analysis

Sometimes, we can understand most about a stock by simply looking at how it has been trading. Looking at the stocks movement on the chart, Puma Biotechnology, Inc. recorded a 52-week high of $98.85. It is now trading 6.8% off that level. The stock is trading $87.01 its 50-day moving average by -5.04%. The stock carved out a 52-week low down at $28.35.

In recent action, Puma Biotechnology, Inc. (PBYI) has made a move of +3.20% over the past month, which has come on Strong relative transaction volume. Over the trailing year, the stock is outperforming the S&P 500 by 47.04, and its gotten there by action that has been less volatile on a day-to-day basis than most other stocks on the exchange. In terms of the mechanics underlying that movement, traders will want to note that the stock is trading on a float of 19.78% with $32.23 Million sitting short, betting on future declines. That suggests something of the likelihood of a short squeeze in shares of PBYI.

See the article here:
Puma Biotechnology, Inc. (PBYI): From Top to Bottom – StockNewsJournal

Recommendation and review posted by Guinevere Smith

Puma Biotechnology to Participate in Panel Discussion at Citi’s Biotech Conference – Business Wire (press release)

Posted: August 31, 2017 at 4:41 pm

LOS ANGELES–(BUSINESS WIRE)–Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will participate in a panel discussion on breast cancer at 9:00 a.m. EDT on Wednesday, September 6, at Citis 12th Annual Biotech Conference in Boston.

A live webcast of the panel discussion will be available on the Companys website at http://www.pumabiotechnology.com. The discussion will be archived on the website and available for 30 days.

About Puma Biotechnology

Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. The Company in-licenses the global development and commercialization rights to three drug candidates PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357. NERLYNX (neratinib) is approved for commercial use by prescription in the United States as extended adjuvant therapy for early stage HER2-positive breast cancer following adjuvant trastuzumab-based therapy and is marketed as NERLYNX. Neratinib is a potent irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2 and HER4. Currently, the Company is primarily focused on the commercialization of NERLYNX and the continued development of its other advanced drug candidates directed at the treatment of HER2-positive breast cancer. The Company believes that NERLYNX has clinical application in the potential treatment of several other cancers that over-express or have a mutation in HER2.

Further information about Puma Biotechnology may be found at http://www.pumabiotechnology.com.

Forward-Looking Statements

This press release and the webcast of the panel discussion contain forward-looking statements, including statements regarding the benefits of NERLYNX and neratinib, the Companys clinical trials and the announcement of data relative to those trials. All forward-looking statements involve risks and uncertainties that could cause the Companys actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors, which include, but are not limited to, the risk factors disclosed in the periodic and current reports filed by the Company with the Securities and Exchange Commission from time to time, including the Companys Quarterly Report on Form 10-Q for the quarter ended June 30, 2017. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company assumes no obligation to update these forward-looking statements, except as required by law.

See more here:
Puma Biotechnology to Participate in Panel Discussion at Citi’s Biotech Conference – Business Wire (press release)

Recommendation and review posted by Guinevere Smith

Powershares Dynamic Biotechnology and Genome Portfolio (PBE) TEMA Trending Higher – FLBC News

Posted: August 31, 2017 at 4:41 pm

Powershares Dynamic Biotechnology and Genome Portfolio (PBE)sTriple Exponential Moving Average has been spotted as trending higher over the past five bars, suggesting that momentum is building for the shares. Triple Exponential Moving Average (also referred to as TEMA) was developed by Patrick Mulloy and was first published in the Technical Analysis of Stocks & Commodities magazine. The main purpose in developing of this indicator was reducing the lag between the indicator and price action by making it fast-acting and more sensitive to market changes. In similar to other moving averages way, the TEMA indicator is used to identify trends and generate trading signals.

The Relative Strength Index (RSI) is another highly popular momentum indicator used for technical analysis. The RSI can help display whether the bulls or the bears are currently strongest in the market. The RSI may be used to help spot points of reversals more accurately. The RSI was developed by J. Welles Wilder. As a general rule, an RSI reading over 70 would signal overbought conditions. A reading under 30 would indicate oversold conditions. As always, the values may need to be adjusted based on the specific stock and market. RSI can also be a valuable tool for trying to spot larger market turns. Powershares Dynamic Biotechnology and Genome Portfolio (PBE) has a 14-day RSI of 63.49, the 7-day is at 73.49, and the 3-day is resting at 85.06.

Powershares Dynamic Biotechnology and Genome Portfolio (PBE) currently has a 14-day Commodity Channel Index (CCI) of 180.47. Active investors may choose to use this technical indicator as a stock evaluation tool. Used as a coincident indicator, the CCI reading above +100 would reflect strong price action which may signal an uptrend. On the flip side, a reading below -100 may signal a downtrend reflecting weak price action. Using the CCI as a leading indicator, technical analysts may use a +100 reading as an overbought signal and a -100 reading as an oversold indicator, suggesting a trend reversal.

Shares of Powershares Dynamic Biotechnology and Genome Portfolio (PBE) have a 200-day moving average of 43.16. The 50-day is 46.48, and the 7-day is sitting at 46.82. Using a bigger time frame to assess the moving average such as the 200-day, may help block out the noise and chaos that is often caused by daily price fluctuations. In some cases, MAs may be used as strong reference points for spotting support and resistance levels.

The Average Directional Index or ADX is technical analysis indicator used to describe if a market is trending or not trending. The ADX alone measures trend strength but not direction. Using the ADX with the Plus Directional Indicator (+DI) and Minus Directional Indicator (-DI) may help determine the direction of the trend as well as the overall momentum. Many traders will use the ADX alongside other indicators in order to help spot proper trading entry/exit points. Currently, the 14-day ADX for Powershares Dynamic Biotechnology and Genome Portfolio (PBE) is 15.56. Generally speaking, an ADX value from 0-25 would indicate an absent or weak trend. A value of 25-50 would indicate a strong trend. A value of 50-75 would signal a very strong trend, and a value of 75-100 would indicate an extremely strong trend. The Williams Percent Range or Williams %R is another technical indicator that may be useful for traders and investors.

The Williams %R is designed to provide a general sense of when the equity might have reached an extreme and be primed for a reversal. As a general observance, the more overbought or oversold the reading displays, the more likely a reversal may take place. The 14 day Williams %R for Powershares Dynamic Biotechnology and Genome Portfolio (PBE) is noted at -1.01. Many consider the equity oversold if the reading is below -80 and overbought if the indicator is between 0 and -20.

Read more here:
Powershares Dynamic Biotechnology and Genome Portfolio (PBE) TEMA Trending Higher – FLBC News

Recommendation and review posted by Fredricko

CAR-T: Novartis prices CTL019 at US$475000 – European Biotechnology

Posted: August 31, 2017 at 4:41 pm

Swiss Novartis AG has received US market authorisation for its first-in-class CAR-T cell therapy Kymriah (tisagenlecleucel-T). As severe cytokine storms seemed to be generally linked to CAR-T therapies such as Kymriah, the FDA also authorised Roches anti-IL-6R antibody Actemra (tocilizumab) as first-in-class treatment to manage them.

Novartis, which received unanimous backing from the FDA ODAC committee for its CAR-T cell therapy in Julyto treat young patients with acute lymphoblastic leukemia (ALL), priced Kymriah at US$475,000 per patient, making it one of the most expensive treatments in the world. The pharma major also agreed with the CMS (US Centers for Medicare & Medicaid Services) that patients who do not respond to its therapy wont be charged. Kymriah consists of autologous T cells which were engineered ex vivoto target the CD19 antigen on B lymphocytes. As the CD19 antibody is linked to a immunostimulatory CD3zeta/CD137 signalling domain, T cells kill B lymphocytes upon binding.

The Novartis CAR-T approval is a significant progress for patients and patient communities of the diseases that late-stage clinical CAR-T therapies are targeting, commented the International Society for Cellular Therapy. Besides ALL, Novartis is seeking approval for tisagenlecleucel-T in non-hodgkin lymphoma and diffuse large B cell lymphoma. In September, the FDA will decide over market authorisation of Kite Pharmas CAR-T cell therapy axicabtagene ciloleucel targeting the CD19 antigen on B lymphocytes.Most recently, the company has been subject to a US$11.9bn take-over bid by Gilead Sciences.

FDA approval for Novartis breakthrough therapy was based on the ELIANA trial in which tisagenlecleucel-T showed a remission rate of more than 80% in 63 ALL patients at three months. As up to now, four deaths caused by CAR-T induced cytokine release syndrome (CRS) occured in clinical trails evaluating different CAR-T therapies. Since additional 44% of patients who were enroled in the ELIANA trial showed grade 3 and 4 CRS, the FDA also expanded the label of Roche/Genentechs RA antibodytocilizumab (Actemra) to treat CAR T cell-induced CRS. Actemra helped 69% of patients to resolve CRS 14 days after they received the monoclonal antibody. Until today, there has never been an FDA-approved treatment to manage severe cytokine release syndrome associated with CAR T cell therapy, which is marked by a rapid onset and can cause life-threatening complications, said Sandra Horning, MD, Chief Medical Officer and Head of Global Product Development at Roche. Today’s approval of Actemra/RoActemra for CRS provides physicians with an important tool to help manage this potentially life-threatening side effect.

According to the FDA, Kymria must be co-administered with Roches immunosuppressive antibody therapy for management of CRS. However, Actemra could not resolve neurotoxicity of tisagenlecleucel-T treatment, which occured in 44% of patients in the ELIANA trial. As manufacturing of Novartis CAR-T cell therapy is lenghty, complicated and only partly reproducible, the 20-25 medical centre expected by Novaertis set to offer the therapy must receive certification before.

Excerpt from:
CAR-T: Novartis prices CTL019 at US$475000 – European Biotechnology

Recommendation and review posted by Guinevere Smith

Hofstra and Northwell rename medical school following $61 million donation – The Island Now

Posted: August 31, 2017 at 4:40 pm

Donald and Barbara Zuckers foundation donated $61 million to the medical school founded by Hofstra University and Northwell Health, the organizations announced on Wednesday, leading to renaming the school for the couple.

Most of the donation or $50 million will go towards a permanent endowment to provide students need-based scholarship support in the Zucker School of Medicine.

Some $10 million meanwhile goes towards creating and endowing the Barbara Hrbek Zucker Emerging Scientists Program at the Feinstein Institute for Medical Research, which is headquartered in Manhasset.

The program is intended to prepare postdoctoral fellows for successful careers and support early career faculty in developing research programs.

More so than any other donors in our history, Don and Barbara Zucker have been extraordinary supporters of causes where we have historically struggled to get financial support, Michael J. Dowling, president and chief executive officer of Northwell Health, said in a statement.

Their latest gifts are a testament to the Zuckers leadership as philanthropists who recognize the vital role of medical education and research in transforming the future of medicine.

Donald Zucker, 86, a New York City real estate developer from Sands Point, and his wife Barbara, donated to Northwell in the past. The couple gave to organizations like the Zucker Hillside Hospital in Glen Oaks, Lenox Hill Hospital in Manhattan and the Elmezzi Graduate School of Molecular Medicine in Manhasset.

Lawrence Smith, the founding dean of the Zucker School of Medicine and physician-in-chief at Northwell Health, said that the couple recognized how important it is to support students financially.

Their generosity will ensure that our medical school will continue to be represented by a highly diverse, talented student body that reflects the communities we serve throughout the New York metropolitan area, Smith said.

Hofstra University and Northwell Health first launched the medical school in 2008. It currently has 400 students enrolled and had more than 7,000 applicants competing for 100 spaces in 2016.

Almost a decade ago, we set out to create a new model of medical education that would improve health care in our region and today we mark another milestone in that journey, said Stuart Rabinowitz, the president of Hofstra University. The Zuckers support solidifies and expands our commitment to train innovative physicians whose backgrounds and experiences are as diverse as the people they treat.

Continued here:
Hofstra and Northwell rename medical school following $61 million donation – The Island Now

Recommendation and review posted by Guinevere Smith

Vacant corner lot by new UB medical school drawing developers’ interest – Buffalo News

Posted: August 31, 2017 at 4:40 pm

A little vacant lot in the Allentown historic district that sits directly across from University at Buffalo’s new medical school is becoming a magnet for offers from real estate developers.

The grassy plot at 942 Main St. which has an overgrown community garden, a bench and a decorative stone wall that proclaims “Allentown” is worth only $29,861, according to city property records.

But because of the uptick in developer interest surrounding the Buffalo Niagara Medical Campus and nearby neighborhoods, an owner of the 32.5-foot-by-118-foot parcel says he’s received offers hovering in the $500,000 range.

Dino Scouras, the co-owner of the Towne Restaurant in Allentown, co-owns the lot with his brother and sister.

In the last two months, the siblings have received three offers for the vacant lot, said Scouras.

“I’m not surprised by the interest,” said Scouras, who owns it along with his brother Paul, and sister, Eleni Konstantopoulos. “That corner is jumping out at everybody.”

Scouras said the family is open to offers on the parcel, along with another vacant corner lot it owns at Park and Allen streets which he can see kitty-corner through a window at the Towne restaurant, a 46-year neighborhood fixture at Allen and Elmwood Avenue.

“We’re not sure if we’d want to build to suit, or sell the property outright,” Scouras said of the 942 Main St. property. “We’re open to offers.”

Asked if the family would consider developing it for its own business interests, he said: “We’re keeping all our options open.”

For years, the corner lot has had four large, white stones to provide a unique, decorative element to the corner. The planting bed and decorative stone wall were created by University at Buffalo School of Architecture and Planning students, guided by professor Brad Wales.

More:
Vacant corner lot by new UB medical school drawing developers’ interest – Buffalo News

Recommendation and review posted by Fredricko


Page 20«..10..19202122..3040..»